Search Results

There are 15693 results for: content related to: Erratum: Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE and Zent CS. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer . 2013;119:3788-96

  1. Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies

    Annals of the New York Academy of Sciences

    Volume 1263, Issue 1, August 2012, Pages: 43–56, Ira V. Gupta and Roxanne C. Jewell

    Version of Record online : 25 JUL 2012, DOI: 10.1111/j.1749-6632.2012.06661.x

  2. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients

    British Journal of Haematology

    Volume 170, Issue 1, July 2015, Pages: 40–49, Anders Österborg, William G. Wierda, Jiří Mayer, Georg Hess, Peter Hillmen, Johannes Schetelig, Anna Schuh, Lukáš Smolej, Christian Beck, Brigitte Dreyfus, Andrzej Hellman, Piotr Kozlowski, Michael Pfreundschuh, Rita Rizzi, Martin Spacek, Jennifer L. Phillips, Ira V. Gupta, Vanessa Williams, Roxanne C. Jewell, Noelia Nebot, Steen Lisby and Martin J. S. Dyer

    Version of Record online : 30 MAR 2015, DOI: 10.1111/bjh.13380

  3. You have free access to this content
    Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL)

    Cancer

    Volume 119, Issue 21, 1 November 2013, Pages: 3788–3796, Tait Shanafelt, Mark C. Lanasa, Timothy G. Call, Anne W. Beaven, Jose F. Leis, Betsy LaPlant, Deborah Bowen, Michael Conte, Diane F. Jelinek, Curtis A. Hanson, Neil E. Kay and Clive S. Zent

    Version of Record online : 6 AUG 2013, DOI: 10.1002/cncr.28292

  4. You have free access to this content
    Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma

    British Journal of Haematology

    Volume 156, Issue 4, February 2012, Pages: 490–498, Matthew J. Barth, Francisco J. Hernandez-Ilizaliturri, Cory Mavis, Ping-Chiao Tsai, John F. Gibbs, George Deeb and Myron S. Czuczman

    Version of Record online : 9 DEC 2011, DOI: 10.1111/j.1365-2141.2011.08966.x

  5. You have free access to this content
    Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

    Arthritis & Rheumatism

    Volume 62, Issue 8, August 2010, Pages: 2227–2238, Mikkel Østergaard, Bo Baslund, William Rigby, Bernadette Rojkovich, Christian Jorgensen, Peter T. Dawes, Charlotte Wiell, Daniel J. Wallace, Søren C. Tamer, Helle Kastberg, Jørgen Petersen and Stanislaw Sierakowski

    Version of Record online : 19 APR 2010, DOI: 10.1002/art.27524

  6. A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia

    American Journal of Hematology

    Volume 91, Issue 10, October 2016, Pages: 1020–1025, Ian W. Flinn, Amy S. Ruppert, William Harwin, David Waterhouse, Steven Papish, Jeffrey A. Jones, John Hainsworth and John C. Byrd

    Version of Record online : 22 JUL 2016, DOI: 10.1002/ajh.24468

  7. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia

    Intervention Review

    The Cochrane Library

    Kathrin Bauer, Michaela Rancea, Verena Roloff, Thomas Elter, Michael Hallek, Andreas Engert and Nicole Skoetz

    Published Online : 14 NOV 2012, DOI: 10.1002/14651858.CD008079.pub2

  8. You have free access to this content
    Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody

    British Journal of Haematology

    Volume 140, Issue 3, February 2008, Pages: 303–312, Wim K. Bleeker, Martin E. Munk, Wendy J. M. Mackus, Jeroen H. N. Van Den Brakel, Marielle Pluyter, Martin J. Glennie, Jan G. J. Van De Winkel and Paul W. H. I. Parren

    Version of Record online : 28 NOV 2007, DOI: 10.1111/j.1365-2141.2007.06916.x

  9. Assessment of the effect of ofatumumab on cardiac repolarization

    The Journal of Clinical Pharmacology

    Volume 55, Issue 1, January 2015, Pages: 114–121, Roxanne C. Jewell, Kevin Laubscher, Eric Lewis, Lei Fang, Zarina Gafoor, Jodi Carey, Astrid McKeown, Sarah West, Oliver Wright, Donna Sedoti, Iestyn Dixon, Charles Scott Hottenstein and Geoffrey Chan

    Version of Record online : 21 AUG 2014, DOI: 10.1002/jcph.376

  10. You have free access to this content
    Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma

    British Journal of Haematology

    Volume 157, Issue 4, May 2012, Pages: 438–445, Myron S. Czuczman, Georg Hess, Ole V. Gadeberg, Lars M. Pedersen, Nancy Goldstein, Ira Gupta, Roxanne C. Jewell, Thomas S. Lin, Steen Lisby, Claus Strange, Kristian Windfeld, Andreas Viardot and for the 409 Study Investigators

    Version of Record online : 13 MAR 2012, DOI: 10.1111/j.1365-2141.2012.09086.x

  11. You have free access to this content
    Chronic lymphocytic leukemia (CLL)—Then and now

    American Journal of Hematology

    Volume 91, Issue 3, March 2016, Pages: 330–340, Kanti R. Rai and Preetesh Jain

    Version of Record online : 22 FEB 2016, DOI: 10.1002/ajh.24282

  12. A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p

    European Journal of Haematology

    Volume 90, Issue 4, April 2013, Pages: 349–350, Konrad Namberger, Lukas Weiss, Barbara Krause, Thomas Melchardt and Richard Greil

    Version of Record online : 14 FEB 2013, DOI: 10.1111/ejh.12065

  13. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies

    Clinical Pharmacology & Therapeutics

    Volume 97, Issue 5, May 2015, Pages: 455–468, Y Wang, LL Zhang, RE Champlin and ML Wang

    Version of Record online : 3 APR 2015, DOI: 10.1002/cpt.85

  14. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis

    The Journal of Clinical Pharmacology

    Volume 54, Issue 7, July 2014, Pages: 818–827, Herbert Struemper, Mark Sale, Bela R. Patel, Mikkel Østergaard, Anders Österborg, William G. Wierda, Anton Hagenbeek, Bertrand Coiffier and Roxanne C. Jewell

    Version of Record online : 28 JAN 2014, DOI: 10.1002/jcph.268

  15. You have free access to this content
    New oral small molecules in the treatment of chronic lymphocytic leukemia

    Cancer

    Volume 121, Issue 12, June 15, 2015, Pages: 1917–1926, Nicole Lamanna

    Version of Record online : 17 FEB 2015, DOI: 10.1002/cncr.29130

  16. Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus–myoclonus

    Pediatric Blood & Cancer

    Volume 58, Issue 6, June 2012, Pages: 988–991, Michael R. Pranzatelli, Elizabeth D. Tate, Shalini Shenoy and Anna L. Travelstead

    Version of Record online : 25 MAY 2011, DOI: 10.1002/pbc.23187

  17. You have free access to this content
    Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study

    American Journal of Hematology

    Volume 90, Issue 5, May 2015, Pages: 417–421, Michael Doubek, Yvona Brychtova, Anna Panovska, Ludmila Sebejova, Olga Stehlikova, Jana Chovancova, Jitka Malcikova, Jana Smardova, Karla Plevova, Pavlina Volfova, Martin Trbusek, Marek Mraz, Denisa Bakesova, Jakub Trizuljak, Marketa Hadrabova, Petra Obrtlikova, Josef Karban, Lukas Smolej, Alexandra Oltova, Eva Jelinkova, Sarka Pospisilova and Jiri Mayer

    Version of Record online : 1 APR 2015, DOI: 10.1002/ajh.23964

  18. You have full text access to this OnlineOpen article
    Novel human antibody therapeutics: The age of the Umabs

    Biotechnology Journal

    Volume 3, Issue 9-10, October 2008, Pages: 1157–1171, Sigrid R. Ruuls, Jeroen J. Lammerts van Bueren, Jan G. J. van de Winkel and Paul W. H. I. Parren

    Version of Record online : 13 AUG 2008, DOI: 10.1002/biot.200800110

  19. You have free access to this content
    Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment

    American Journal of Hematology

    Volume 90, Issue 5, May 2015, Pages: 446–460, Michael Hallek

    Version of Record online : 23 APR 2015, DOI: 10.1002/ajh.23979

  20. Ibrutinib, Obinutuzumab, Idelalisib, and Beyond: Review of Novel and Evolving Therapies for Chronic Lymphocytic Leukemia

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 34, Issue 12, December 2014, Pages: 1298–1316, Clement Chung and Rosetta Lee

    Version of Record online : 30 OCT 2014, DOI: 10.1002/phar.1509